FactoWiki

Berberine side effects and drug interactions

Berberine’s most common side effects are digestive — constipation, diarrhoea and cramping. Its more important risk is interactions: in a clinical study, two weeks of berberine 300 mg three times daily reduced the activity of three major drug-metabolising liver enzymes (CYP2D6, CYP2C9 and CYP3A4), which can raise blood levels of many medicines. It can also add to diabetes medicines, and it should not be used in pregnancy, breastfeeding or infants.

This article answers one question. For what Berberine is, where it comes from and its other uses, see the Berberine ingredient guide.

Key findings

  • Repeated berberine dosing inhibited CYP2D6, CYP2C9 and CYP3A4 in healthy volunteers.
  • Combining berberine with glucose-lowering medicines can increase the risk of low blood sugar.
  • Berberine should not be used in pregnancy, breastfeeding or in infants.
  • Digestive side effects are the most commonly reported adverse effects.

What human research shows about interactions

In a randomised crossover study of healthy men, researchers gave berberine 300 mg three times daily for two weeks and then used standard probe drugs to measure enzyme activity (Guo et al., Eur J Clin Pharmacol 2012). Compared with the control phase, the dextromethorphan urinary ratio rose about ninefold (reduced CYP2D6 activity), the losartan metabolite ratio doubled (reduced CYP2C9 activity), and midazolam exposure increased by around 40% (reduced CYP3A4 activity). These enzymes metabolise a large share of prescription medicines, so inhibition can raise drug levels and side effects. The Endotext (NCBI Bookshelf) review also highlights berberine’s inhibition of drug-metabolising enzymes as a reason for caution with multiple medicines.

Evidence table

Study or sourcePopulationWhat was testedMain resultLimitations
Guo et al., Eur J Clin Pharmacol 2012Healthy men (crossover)Berberine 300 mg three times daily for 2 weeks; probe drugsCYP2D6 ↓ (dextromethorphan ratio ~9×), CYP2C9 ↓ (losartan ratio ~2×), CYP3A4 ↓ (midazolam AUC ~+40%)Small; healthy volunteers; single regimen
ClinicalTrials.gov NCT02365480 protocolSummary of earlier clinical useOral doses up to 1,500 mg/day, up to 3 monthsMild–moderate constipation in 3–8%Background summary
NCCIH berberine pageSafety guidanceNot for pregnancy, breastfeeding or infants; discuss with provider if taking medicinesGuidance summary

Common side effects

Medicines to check with a pharmacist

Who should avoid berberine or seek advice first

Limitations

Practical label reading

Related: berberine evidence review · berberine dosage for blood sugar · berberine guide

Frequently asked questions

Does berberine interact with medications?

Yes. It reduced the activity of CYP2D6, CYP2C9 and CYP3A4 in a human study and can add to diabetes medicines.

Can I take berberine with metformin?

Only with your clinician’s agreement and glucose monitoring, because effects on blood sugar can add together.

What are the most common berberine side effects?

Digestive effects such as constipation, diarrhoea and cramping.

Is berberine safe in pregnancy?

No. It should not be used in pregnancy, breastfeeding or by infants.

Does goldenseal contain berberine?

Yes; goldenseal and several other plants contain berberine, so the same interaction concerns may apply.

References

  1. Guo et al., Eur J Clin Pharmacol 2012. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol.
  2. Endotext (NCBI Bookshelf): complementary and integrative approaches for type 2 diabetes.
  3. NCCIH berberine page.
  4. ClinicalTrials.gov NCT02365480 protocol.